CN106963547A - The intelligent eye-cover for weak sight of monitoring in real time - Google Patents
The intelligent eye-cover for weak sight of monitoring in real time Download PDFInfo
- Publication number
- CN106963547A CN106963547A CN201710021752.XA CN201710021752A CN106963547A CN 106963547 A CN106963547 A CN 106963547A CN 201710021752 A CN201710021752 A CN 201710021752A CN 106963547 A CN106963547 A CN 106963547A
- Authority
- CN
- China
- Prior art keywords
- amblyopia
- eyeshade body
- monitoring
- cover
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 81
- 210000001747 pupil Anatomy 0.000 claims abstract description 19
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 5
- 210000003128 head Anatomy 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 206010049244 Ankyloglossia congenital Diseases 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000009487 Amblyopia Diseases 0.000 description 118
- 238000011282 treatment Methods 0.000 description 59
- 238000002560 therapeutic procedure Methods 0.000 description 45
- 230000004438 eyesight Effects 0.000 description 37
- 230000001225 therapeutic effect Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 238000011160 research Methods 0.000 description 15
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 229930003347 Atropine Natural products 0.000 description 13
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 13
- 229960000396 atropine Drugs 0.000 description 13
- 230000000007 visual effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- AZRZBCASYOBNKQ-UHFFFAOYSA-N 6-chloro-3,5-diaminopyrazine-3-carboxamide Chemical compound CN(C)C(N)=NC(=O)C1=NC(Cl)=C(N)N=C1N AZRZBCASYOBNKQ-UHFFFAOYSA-N 0.000 description 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
- 229960004502 levodopa Drugs 0.000 description 10
- 208000014733 refractive error Diseases 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 208000029091 Refraction disease Diseases 0.000 description 6
- 230000004430 ametropia Effects 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 206010001912 Amblyopia strabismic Diseases 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- 206010025421 Macule Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 201000009406 ametropic amblyopia Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- -1 levodopa amine Chemical class 0.000 description 5
- 201000009485 suppression amblyopia Diseases 0.000 description 5
- 230000004382 visual function Effects 0.000 description 5
- 206010059397 Antimetropia Diseases 0.000 description 4
- 208000006550 Mydriasis Diseases 0.000 description 4
- 206010047571 Visual impairment Diseases 0.000 description 4
- 201000009310 astigmatism Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 201000009407 disuse amblyopia Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000000162 simple eye Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 210000000857 visual cortex Anatomy 0.000 description 4
- 208000004350 Strabismus Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000000642 iatrogenic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002189 macula lutea Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 206010013082 Discomfort Diseases 0.000 description 2
- 208000010415 Low Vision Diseases 0.000 description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004303 low vision Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 206010029864 nystagmus Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- 241000834283 Amblyopsidae Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010015996 Eyelid ptosis congenital Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 206010038897 Retinal tear Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010002537 anisometropia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000003002 congenital ptosis Diseases 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000001882 hereditary congenital 1 ptosis Diseases 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/04—Eye-masks ; Devices to be worn on the face, not intended for looking through; Eye-pads for sunbathing
- A61F9/045—Eye-shades or visors; Shields beside, between or below the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/113—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for determining or recording eye movement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/14—Arrangements specially adapted for eye photography
-
- G—PHYSICS
- G08—SIGNALLING
- G08B—SIGNALLING OR CALLING SYSTEMS; ORDER TELEGRAPHS; ALARM SYSTEMS
- G08B21/00—Alarms responsive to a single specified undesired or abnormal condition and not otherwise provided for
- G08B21/18—Status alarms
- G08B21/24—Reminder alarms, e.g. anti-loss alarms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Emergency Management (AREA)
- General Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Business, Economics & Management (AREA)
- Human Computer Interaction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of intelligent eye-cover for weak sight of monitoring in real time, including eyeshade body, the monitor of monitoring pupil position is provided with eyeshade body, power supply, buzzer, red prompt light and green warning light, eyeshade body interior is built-in with the monitoring chip for analyzing pupil position data, the signal input port of monitoring chip is connected by the output port of the data wire built in eyeshade body and monitor, the power end of monitoring chip by the wire and power supply built in eyeshade body just, negative pole is connected, a number current output terminal of the monitoring chip is connected by the power interface of the wire built in eyeshade body and buzzer, No. two current output terminals of the monitoring chip are connected by the wire built in eyeshade body and the power interface of red prompt light, No. three current output terminals of the monitoring chip are connected by the wire built in eyeshade body with the power interface of green warning light.The beneficial effects of the invention are as follows effectively reduce the dependence of patient.
Description
Technical field
The present invention relates to vision correction and therapy field, particularly a kind of intelligent eye-cover for weak sight of monitoring in real time.
Background technology
First, the classification of amblyopia
The characteristics of amblyopia caused by the different causes of disease has different, under amblyopia is divided into by the clinical sign merged according to amblyopia
Row are several:
1. strabismic amblyopia:Strabismic amblyopia is one of most common amblyopia.When amblyopia occurs for simple eye or eyes, to regarding
The visual function development impact of Yezhong centre is larger, the contrast of strabismic amblyopia smaller [5] to the visual function development impact on visual field periphery
The infringement of susceptibility is main in central vision field [6].Research shows, the nearly parallax free of strabismic amblyopia infant, crossed disparity, non-friendship
Pitch parallax and remote stereopsis is worst [7], main cause have impact on the normal of stereoscopic vision for the possible caused simple eye suppression of strabismus
Development, and stereopsis different degrees of infringement [8] is occurred.
2. anisometropic amblyopia:Anisometropic amblyopia is simple eye property amblyopia, because the antimetropias of two are larger,
The image of two macula luteas formation is clear, and the high eye-shaped of general diopter is into amblyopia.Weakley is inquired into be caused by ametropia
The reason for amblyopia, even finding long sight antimetropia as low as 1.0D, myopic anisometropia as low as 2.0D and astigmatism
Antimetropia as low as 1.5D is also enough to produce amblyopia [9].Just kingfisher English et al. also research finds its amblyopia of anisometropic amblyopia person
Optic disk peripheral retinal tear nerve fibre layer (RNFL, the Retinal Nerve Fiber Layer) thickness and central fovea of macula of eye
Thickness is thickened compared with normal eyes, and hypermetropic astigmatism amblyopia eye is thick [10] compared with simple hypermetropia amblyopia eye.
3. form deprivation amblyopia:Form deprivation amblyopia is a kind of most rare but the most serious amblyopia.Due to the optical axis
Block or the macula lutea imaging gross distortion caused by reason such as ametropia causes visual deprivation.Congenital cataract, corneal clouding,
Congenital ptosis, vitreous hemorrhage, iatrogenic eyelid suture or covering and seriously ametropia can cause shape to be felt
After Monocular Deprivation [11].
4. ametropic amblyopia:Ametropic amblyopia is rescued or corrected improper and drawn by the ametropia not row of eyes
The amblyopia risen.It is most commonly in the children of hyperpresbyopia or astigmatism.
5. the linear amblyopia of meridian:Astigmatism without correction can cause selective visual deprivation, so that it is linear to produce meridian
Amblyopia.It is uncommon Unilateral amblyopia including (1) non-specific amblyopia, through occlusion therapy, eyesight improving, but when covering stops
Causing Amblyopia Recurrence after only;(2) organic amblyopia, such as neonate's retina, macula lutea, regarding road bleeding;(3) secondary to nystagmic weak
Can all cause low vision depending on, dominant or latent nystagmus, but nystagmus the reason for be low vision or result still not
It is clear.
2nd, the pathogenesis of amblyopia
It is not difficult to find out that all amblyopias are all due to lose normal image to central fovea of retina according to the classification of foregoing amblyopia
Stimulation, hinder caused by the normal development of visual performance.Von Noorden think that the pathogenesis of amblyopia, including shape are felt
Deprive or eyes reciprocation is abnormal [12].Both can individually occur can also be while occur.
1. visual deprivation:Visual deprivation is typically due to block what optical axis path was caused, such as cataract, vitreous hemorrhage,
Corneal clouding or serious ptosis, it is also possible to being caused by serious antimetropia.Experimental caused by different pathogeny
In amblyopia, it is identical to have many performances, therefore pathogenesis is also identical, i.e. visual deprivation [11].During treatment amblyopia
Strong eye-shade lid can also cause iatrogenic form deprivation amblyopia, due to caused by long-term occlusion therapy or simple eye atropine mydriasis
Iatrogenic form deprivation amblyopia turns into occlusion amblyopia [13].
2. the eyes effect of vying each other:Under normal circumstances, the eyes visual cell positioned at foreign journals or cortex is in flat
Weighing apparatus state.When early vision occurs abnormal after birth, it is deprived of the cell of eye and is on a sticky wicket in two competition processes,
Thus grow hindered, gradually form amblyopia.
3. it is other:Numerous studies have proven to the brain visual cortex of amblyopia patient and there is structure and dysfunction in recent years,
There is a small amount of document to think that its retinal thickness is also [14-15] changed.Salchow etc. research also confirms that retina neural
Fiber layer thickness is relevant with age and refractive status, [16-17] relevant with the mechanism of amblyopia.
3rd, the treatment of amblyopia
1. correction of refractive errors:Most amblyopia patients are with different degrees of ametropia.Any amblyopia is controlled
The first step for the treatment of be all make clearly image be incident upon on macular area central fovea, so all obvious refractive medias must be removed
Muddiness, and with frame eyeglasses, contact lens (RGP, Rigid Gas Permeable contact lens) or dioptric hand
The complete correction of refractive errors of art mode.If not, the method for other any treatment amblyopias all will be hard to work.Moseley etc.
The eyesight [18] of each type amblyopia can effectively be improved by thinking the correction of refractive errors of specification.Pradhan etc. suffers from treatment
Compared during youngster's amblyopia with frame eyeglasses and RGP, as a result show the cure rates of RGP groups and efficient apparently higher than frame eyeglasses group
[19].It is old for et al. research also confirm that RGP than frame eyeglasses has more preferable vision when treating height anisometropic amblyopia
Quality [20].
2. occlusion therapy:Begin to use occlusion therapy from deBuffon, so far the existing history of more than 200 years, be still so far
The method of maximally effective treatment children whose monocular amblyopia.According to the covering time that the age of patient is different with the difference selection of two eye visions.
There is very big dispute [21-22] for covering time length, many doctors think that the smaller time covered at age should just get over
It is short, to older children, start to carry out the covering of 6 hours or longer time daily, later according to infant to treatment
Reaction reduces the time covered daily.U.S. pediatric ophthalmology disease research group (PEDIG, Pediatric Eye Diseases
Investigator Group) the daily therapeutic effect for covering 2 hours and covering 6 hours of investigation contrast moderate children with amblyopia, hair
Existing two groups of infants are after treatment 4 months, and eyesight is significantly improved [23], and many people it is thus regarded that covering 2 hours and hiding daily
The lid effect of 6 hours is identical.Subsequent PEDIG has been investigated again to carry out covering within 6 hours and complete daily to the infant with serious amblyopia
Its occlusion therapy, eyesight improves also almost identical [24] after 4 months.Matta et al. researchs also confirm that part-time hides simultaneously
Lid effect is substantially better than whole day and covers [25].To receive occlusion therapy infant should follow-up closely because strong eye has covered
Into the risk [26] of amblyopia.Occlusion therapy is always the Main Means of amblyopia treatment, why is used by numerous oculists,
It is and the side effect without whole body and not expensive because this method curative effect really.Occlusion therapy major defect be infant according to
It is poor from property, treatment is mismatched, infant is often removed or opened eyeshade and spies on, and these ways can all cause under occlusion therapy validity
Drop, in addition it is invalid.
3. penalization:Penalization is by medicine, glasses or both and with the eye-blurred for causing strong eye, by constraining
It is good for eye and encourages, strengthens using amblyopia eye.
3.1 medicine penalizations:The most frequently used preparation of medicine penalization is 1% atropine eyedrops, causes pupil to include about
Flesh and ciliary muscle relaxation, mydriasis constrain strong near soon, force patient near soon with amblyopia.AR Medghalchi are to 4-10
The amblyopia patient in year uses atropine and occlusion therapy at random, and result of study shows atropine mydriasis and occlusion therapy 2 times a week
Therapeutic effect is identical [27].PEDIG has carried out a scale trials for the infant of moderate amblyopia and shown, atropine
There was no significant difference [28] for penalization and occlusion therapy therapeutic effect.Repka etc. is applied to the moderate and severe degree of amblyopia children of 3-12 Sui
Atropine penalization and occlusion therapy are contrasted, and as a result show that atropine can significantly improve the eyesight of moderate children with amblyopia, and
Age is smaller, and curative effect is better, and the therapeutic effect of atropine and occlusion therapy is close [29].The swallow amblyopia to 7-14 Sui for army building et al.
Infant progress atropine, which constrains, treats and occlusion therapy, treatment results two groups of therapeutic effect no significant differences of discovery, and two groups
Compliance is respectively 95.2% and 83.1%, it can be seen that the compliance of atropine group is better than occlusion therapy group [30].From many
Atropine penalization and occlusion therapy therapeutic effect no significant difference are found in research, and the former has more preferable compliance, easily
Receive in by infant, it is psychosocial on infant influence it is smaller, can as occlusion therapy alternative medicine be applied to compliance compared with
The children of difference.In addition, photophobia, being blurred, part infant occur after infant atropine mydriasis it is possible that conjunctival congestion,
The allergic symptoms such as flush, heating, due to build-up effect it is possible that atropinism phenomenon when being used for a long time atropine,
So clinically when using atropine penalization, above-mentioned adverse reaction should be taken into account.
3.2 penalization:Penalization refers to change the glasses of strong eye or the number of degrees of contact lense, generation picture
It is fuzzy, improve the competitive advantage of amblyopia eye.Penalization can be used alone, but it is more be and medicine penalization joint
Using.The oppressive shortcoming of single use optics is that infant is removed glasses or spied on by glasses in order to avoid blurring in an image, and
Penalization combination medicine penalization is the strong means [31-33] for treating amblyopia.
4. drug therapy:There is trial drug to treat amblyope in recent years.Clinical the most frequently used medicine is levodopa at present
Amine and CDPC.
4.1 levodopa amine:Levodopa amine is the precursor substance of dopamine.Levodopa amine can pass through blood-brain barrier generation
Thank as dopamine, dopamine is neurotransmission agent, participates in the conduction of central nervous system nerve impulsion, is played in visual development
Important function.The animal model of After Monocular Deprivation is divided into administration group and control group by Li R, and administration group gives levodopa 30 days,
Control group is not administered, and as a result finds the increase of administration group visual cortex expression of nerve growth, the nerve cell reparation [34] of damage.
Illustrate that levodopa can suppress amblyopia by increasing visual cortex expression of nerve growth and repairing the nerve cell of damage
Progress, so as to reach the purpose for the treatment of amblyopia.
4.2 CDPC:CDPC is that lecithin is synthesized before necessary coenzyme, phospholipid phosphatidyl choline
Body, can strengthen the stability of neuronal cell film, and the conversion of catecholamine and serotonin is can adjust in human body, stimulate DOPA
Amine is metabolized, so as to improve visual function [35].The complex treatment of CDPC joint and list are applied respectively in Wang Huan swallows et al. research
Pure 50 above the average age for marriage children with amblyopia of Comprehensive Therapy for Treatment, it is respectively 65.6% and 12.5% to be as a result shown with efficiency, therapeutic alliance group
Eyesight, VEP are significantly improved [36].He Zhaoyan etc. treats the treatment of amblyopia by studying oral CDPC
Imitate total effective rate 70%, hence it is evident that higher than control group effective percentage 42.5% [37].Research illustrates that CDPC treats youngster above
Virgin amblyopia determined curative effect, and CDPC toxicity is low, few side effects, so can clinically be directed to children age and adaptation
Property is used.
4.3 drug combination:The purpose of amblyopia treatment, is not only the eyesight of amblyopia patient to be improved, mainly still to set up
Normal Binocular vison, improves the visual function of eyes.Zhang Xiying et al. thinks levodopa amine joint CDPC treatment children
Amblyopia, while visual acuity in child patient is improved, also improves frequency [38] between infant CSF low-to-medium altitude.Mohammad A couple
The moderate children with amblyopia of more than 12 years old gives " occlusion therapy+levodopa " and simple occlusion therapy 6 weeks respectively, as a result finds to hide
The lid therapy joint more simple occlusion therapy therapeutic effect of levodopa is good [39].Fresina etc. is oral to 5-10 Sui children with amblyopia
CDPC combines occlusion therapy, and the therapeutic effect that control group is only given two groups after occlusion therapy, 30d is close, is compareed during 90d
Group eyesight is on a declining curve, it is believed that CDPC joint occlusion therapy stability is better than simple occlusion therapy [40].
5. visual-stimulating method:The scholars of univ cambridge uk devise a new amblyopia therapeutic equipment, and (Cam, which is regarded, to be stimulated
Instrument), stimulate amblyopia eye to improve eyesight by the use of the different square wave bar grid of hard, spatial frequency as stimulus.Stimulation instrument
Bar grid can be rotated, and most of visual cell is all trained.The bar grid for the highest spatial frequency that can be recognized with infant are as threshold
Value, lid dominant eye during treatment does not need lid dominant eye, switching on power makes bar grid disc spins on ordinary days, and infant is with amblyopia eye according to vinyl disc
On pattern draw, 7 minutes every time, 1 time a day or 2-3 times weekly.Typically do two or three times, eyesight can increase.This treatment
Method is preferably adapted to watching attentively property and ametropic amblyopia centered on card, and paracentral fixation person's effect is poor.The effect machine of this therapy
System, awaits further research.
6. red filter treatment:Red filter treatment is designed according to the anatomical physiology characteristic of retina.Macula lutea
Center only has cone cell, is recessed to peripheral retina from center, cone cell density drastically declines, and rod cell gradually increases
It is many.Rod cell is insensitive to feux rouges, and the cone cell of only central fovea is most sensitive, ordinary ray by Red lightscreening plate it
Afterwards, the red light irradiation of certain wavelength on retina, can promote paracentral fixation eye it is spontaneous be changed into central fixation.Note at center
After change, continuation is treated with covering method.Depth myopia does not apply to this therapy, because plus after Red lightscreening plate, it is seen that light
Reduce, eyesight can further decline, and cause moving difficulty.
7. Haidinger brush:Haidinger brush is to produce a light using special optical principle and retina entopic phenomenon
A kind of visual stimulator of brush.Using up brush stimulates macula retinae central fovea, improves the resolving power of central fovea of macula, Shi Pang centers
Watch attentively and switch to central fixation.
8. after image therapy:Strong light stimulation based retinal is used, central fovea of macula is protected from strong light stimulus by blackspot, and strong light is only
Paracentral fixation point and peripheral retina can be stimulated, peripheral retina produces after image, in holddown, at the same time, training
Central fovea function, improves the consciousness function of central fovea of macula, paracentral fixation is switched to central fixation.Li Jie et al. is to 60 sides
The central fixation treatment of amblyopia in children result display children with amblyopia application after image that the age is smaller, paracentral fixation degree is lighter is treated
Method therapeutic effect is better [41].
9. composite treatment:Composite treatment be will cover etc. the optical instruments such as traditional remedies and red sudden strain of a muscle, after image, Haidinger brush with
And a kind of method being combined finely is trained, by removing the suppression of amblyopia eye, set up binocular single vision and improve eyesight.Xu Xinghui
Et al. 255 children with amblyopia are used with composite treatment, research finds that the age is smaller, and amblyopia degree is lighter, and effect is better, and bends
Positivity amblyopia cure rate is not apparently higher than strabismic amblyopia and ametropic amblyopia [42] for light, this result of study and Yuan Jing [43]
Result with Comprehensive Therapy for Treatment children with amblyopia is consistent.Research shows that composite treatment is effective to treatment infant amblyopia above, can
The therapeutic scheme of individuation is selected for infant amblyopia degree and species.
10. Chinese traditional treatment:The pathogenic factor [44] of amblyopia is said in the traditional Chinese medical science, main and inadequate natural endowment, the shortage day after tomorrow take good care of or
Function is extremely closely related, or deficiency of liver-blood or kidney essence deficiency or Spleen-Qi Deficiency qi and blood biochemistry lack strength, cause vital essence not
Mesh can be reached, mesh, which loses to moisten, supports caused.Poplar build virtue et al. think amblyopia treatment should using filling liver kidney, nourishing the blood and yin, dredging the channel as
Main [45].Zhao Yucheng et al. strong bright soup (Chinese yam, keel, prepared rhizome of rehmannia, chrysanthemum, Semen Cuscutae, Fu for taking good care of liver, the cloudy kidney of nourishing
Siberian cocklebur etc.) treatment amblyopia, effective percentage up to 95.8% [46].In addition to treatment by Chinese herbs, also acupuncture and moxibustion therapy, point stimulating therapy.
Wang Yan et al. carries out electric pulse stimulation treatment to children with amblyopia in temple, and total effective rate is up to 69.7% [47] after treatment half a year.
Zhang Mao plum et al. with ear pressure bean ruling by law treat children's myopia, by using Wang Anyi oppress the ear acupuncture point, and reach heat,
Bitterly, sour, swollen effect, treatment amblyopia effective percentage is 69.7% [48].
11.iPad is treated:IPad treatment anisometropic amblyopias after the improvement of Handa T et al. current research, improvement
IPad afterwards is the LCDs making by removing polarizer layer, and patient needs to wear on a kind of special glasses, amblyopia eye
Eyeglass is that eyeglass is to reduce the wave filter of light on a polaroid filter, normal eyes, and this glasses can also be instructed only for weak
There are 5 eyesights to be improved in the training game carried out depending on eye, 7 children with amblyopia of this research observation, eyesight improves average
It is worth for 0.38 [49].The method can improve the interest of training, add the compliance of infant, and research rank is still at present
Section.
Continuous intensification with the mankind to amblyopia mechanism, the method for the treatment of amblyopia is also increasingly enriched at present, but hides
Lid therapy is still the leading therapy for the treatment of amblyopia after correction of refractive errors, auxiliary to treat otherwise, and according to the first visit of children with amblyopia
Age, eyesight, amblyopia type, refractive status, amblyopia degree and nature of fixation etc. formulate individualized treatment scheme.In vision hair
Early to find in the sensitive periods educated, early diagnosis, early treatment, method is proper, and the treatment works well for most of infant.But amblyopia has multiple
Hair tendency, before vision is without maturation, the amblyopia each cured is likely to recurrence, so the follow-up of each children with amblyopia is seen
Examine until the vision maturity period.There is also moderate and severe degree of amblyopia, older infant therapeutic effect be bad, compliance for amblyopia treatment simultaneously
The problems such as difference, it would be highly desirable to which we further study.
Although existing occlusion therapy has simple and convenient, spend less, it is effective a little, itself also have as follows
Shortcoming;Shortcoming 1. influences outward appearance;2. continuing to employ the poor amblyopia eye fixation of eyesight, the studying and living of patient is influenceed, is difficult to adhere to,
But the problem of compliance, there is directly hardness effect to therapeutic effect;3. it is unfavorable to setting up visual function to cover for a long time;So, it is clinical
The design of such a dose-effect relationship that can be embodied and cover is needed to promote the standardization of amblyopia treatment.
The content of the invention
The invention aims to solve the above problems, a kind of intelligent eye-cover for weak sight of monitoring in real time is devised.
Realize above-mentioned purpose the technical scheme is that, a kind of intelligent eye-cover for weak sight of monitoring in real time, including eye
Cover body, monitor, power supply, buzzer, red prompt light and the green that monitoring pupil position is provided with eyeshade body is carried
Show lamp, eyeshade body interior is built-in with the monitoring chip for analyzing pupil position data, the signal input port of monitoring chip
Connected by the output port of the data wire built in eyeshade body and monitor, the power end of monitoring chip passes through in eyeshade body
The wire and the positive and negative electrode of power supply put are connected, and a current output terminal of the monitoring chip passes through built in eyeshade body
The power interface connection of wire and buzzer, No. two current output terminals of the monitoring chip pass through leading built in eyeshade body
Line and the power interface of red prompt light are connected, and No. three current output terminals of the monitoring chip pass through built in eyeshade body
Wire is connected with the power interface of green warning light.
The monitor is the minisize pick-up head with detection pupil position function.
The monitor is the minisize pick-up head with detection pupil position function.
The monitor is model TE810H microcam.
The monitoring chip is the model HG768 of magnificent health electronics production monitoring chip.
The monitoring chip carries out wireless data transmission by the wireless module built in it by LAN and computer.
The red prompt light and green warning light are all the LED luminescent crystals using silica gel parcel.
The eyeshade body covers eyes by way of frenulum.
The eyeshade body is the rectangular sheet structure being made of elastic cotton or cloth, and the edge of eyeshade body
Handled by chamfering structure.
The power supply is lithium battery, and the lithium battery is detachably arranged on eyeshade body.
The monitor collection iris positional information or infrared reflection information or eye move number information, and the information is passed
It is defeated by the position that monitoring chip analyzes pupil.
The intelligent eye-cover for weak sight of real-time monitoring made using technical scheme, can be good at solving to hide
The compliance of lid process patient, monitoring is covered in real time degree, the amount for scientifically quantifying covering, time and the dose-effect pass by the two
System is intelligently applied in the daily treatment of patient, and doctor can change according to the change of illness state for the treatment of and cover over the course for the treatment of
Time, degree, reach real-time monitoring, improve the therapeutic effect covered.
Brief description of the drawings
Fig. 1 is the structural representation of the embodiment 1 of the intelligent eye-cover for weak sight of real-time monitoring of the present invention;
Fig. 2 is the structural representation of the embodiment 2 of the intelligent eye-cover for weak sight of monitoring in real time shown in the present invention;
Fig. 3 is the structural representation of the embodiment 3 of the intelligent eye-cover for weak sight of monitoring in real time shown in the present invention;
Fig. 4 is the structural representation of the embodiment 4 of the intelligent eye-cover for weak sight of monitoring in real time shown in the present invention;
Fig. 5 is the structural representation of the embodiment 5 of the intelligent eye-cover for weak sight of monitoring in real time shown in the present invention;
In figure, 1, eyeshade body;2nd, monitor;3rd, power supply;4th, buzzer;5th, red prompt light;6th, green warning light;7、
Monitoring chip.
Embodiment
Embodiment 1
The present invention is specifically described below in conjunction with the accompanying drawings, as shown in figure 1, a kind of intelligent amblyopia of monitoring in real time is covered
Eyeshade, including eyeshade body 1, the eyeshade body are used to eyes all standing and lighttight full-time covering type eyeshade, in eyeshade
Monitor 2, power supply 3, buzzer 4, red prompt light 5 and the green warning light 6 of monitoring pupil position, eyeshade are provided with body
Body interior is built-in with the monitoring chip 7 for analyzing pupil position data, and the signal input port of monitoring chip passes through eyeshade
The output port connection of data wire and monitor built in body, the power end of monitoring chip passes through the wire built in eyeshade body
It is connected with the positive and negative electrode of power supply, a current output terminal of the monitoring chip passes through the wire built in eyeshade body and honeybee
The power interface connection of ring device, No. two current output terminals of the monitoring chip pass through the wire built in eyeshade body and red
The power interface connection of warning light, No. three current output terminals of the monitoring chip by the wire built in eyeshade body with it is green
The power interface connection of color warning light.Wherein, the monitor 2 is the minisize pick-up head with detection pupil position function;Institute
It is the minisize pick-up head with detection pupil position function to state monitor 2;The monitor 2 is that the miniature of model TE810H is taken the photograph
Camera;The monitoring chip 7 is the model HG768 of magnificent health electronics production monitoring chip;The monitoring chip 7 is by it
The wireless module put carries out wireless data transmission by LAN and computer;The red prompt light 5 and green warning light 6 are all
It is the LED luminescent crystals wrapped up using silica gel;The eyeshade body 1 covers eyes by way of frenulum;The eyeshade body 1
It is the rectangular sheet structure being made of elastic cotton or cloth, and the edge of eyeshade body is handled by chamfering structure;Institute
Power supply 3 is stated for lithium battery, the lithium battery is detachably arranged on eyeshade body;The collection iris of the monitor 2 position letter
Breath or infrared reflection information or eye move number information, and transmit this information to the position that monitoring chip analyzes pupil.
The characteristics of the technical program be on eyeshade body increase monitor 2, power supply 3, buzzer 4, red prompt light 5,
The structure of green warning light 6 and monitoring chip 7, monitor gathers the iris positional information or infrared reflection information of patient's eye
Or eye moves number information, and the monitoring core for the model HG768 that above- mentioned information is produced by data line transfer to magnificent health electronics
Piece, the chip obtains the actual location data of patient s pupil by processing and computing to gathered data, and monitoring chip will be obtained
Actual location data and the position data of theory setting be compared, if eyeshade body wearing position is abnormal, then actual
Position data and the position data of theory setting have notable difference then to control buzzer and red prompt light to send prompting and alarm,
Inform that patient's eyeshade body is worn incorrect;If eyeshade body is worn correctly, then actual location data and theory setting
The identical then green warning light of position data lights, and will not send alarm.Meanwhile, monitoring chip can lead to the actual location data
The computer system that its internal wireless module is sent in LAN is crossed, healthcare givers can be adjusted specifically by the data
Therapeutic scheme and setting monitoring chip in data.
In the technical program, monitor number of times is moved by iris tracking or infrared ray or eye come monitor eyeshade whether
Position, automatic alarm or prompting when finding that eyeshade is not in place.Designed intelligent eyeshade can complete real-time monitor, in fact
Shi Jilu, record result can be alerted, be accumulated, and backstage can change treatment procedure according to change of illness state.Doctor can adopt
Covering quantized data is inputted into monitoring chip with personalized therapy program, eye is adjusted by the software degree in monitoring chip
The monitoring therapeutic state of cover, so as to realize that treatment is controllable.After eyeshade is in vitro, monitor can not collect pupil information, monitor core
Piece will start buzzer and send tweeting sound, it is known that healthcare givers cancels the alarm shape of monitoring chip internal program by computer
State.Eyeshade deadweight is no more than 10 grams and washable, and power supply uses detachable lithium battery, monitor, red prompt light,
Green warning light, buzzer and monitoring chip all use water-proofing treatment, for example, can be wrapped up said elements using transparent silica gel
Waterproof action is played, so that it is guaranteed that eyeshade can realize periodic cleaning, used eyeshade bulk material is lossless to eye
Wound, it is non-stimulated, do not produce radiation to retinal development, outward appearance is portable, can detain and be through on former glasses, pluck and wear facility.Doctor is controlling
Doctor can change the time covered, degree according to the change of illness state for the treatment of during treatment, reach real-time monitoring, improve what is covered
Therapeutic effect.So, clinic needs the design of such a dose-effect relationship that can be embodied and cover to promote the rule of amblyopia treatment
Generalized, will change the therapeutic effect of whole 40,000,000 children with amblyopia, substantially reduce the lifelong damage that amblyopia is caused to children's vision
Wound.
Patient, so-and-so, man, 4 years old, the amblyopia of central fixation property ametropic was, it is necessary to which whole day is covered, and we just design
Monitor covering time and covering amount, cover quality and covering the prompting omitted for whole day, it is ensured that occlusion therapy is whole, high-quality
Complete, when abandoning from overcover occurs in patient, intelligent eyeshade sends the warning prompting patient that blows a whistle and restarted newly at once
Treatment.Design covers total amount, component, covering degree is covered daily, quality is covered, it is ensured that the quantization covered daily is implemented.
Embodiment 2:
Patient so-and-so, female, 5 years old, the amblyopia of central fixation property ametropic are, it is necessary to which whole day is covered, and we just design
Monitor covering time and covering amount, cover quality and covering the prompting omitted for whole day, it is ensured that occlusion therapy is whole, high-quality
Complete, when abandoning from overcover occurs in patient, intelligent eyeshade sends the warning prompting patient that blows a whistle and restarted newly at once
Treatment.Design covers total amount, component, covering degree is covered daily, quality is covered, it is ensured that the quantization covered daily is implemented.Hide
Lid is only limited to some quadrant, this kind of using clinically few.As shown in Fig. 2 monitor to be arranged on to the upper left of eyeshade body
Angle, forms quadrant covering type eyeshade, other are same as Example 1.
Embodiment 3
As shown in figure 3, eyeshade body will be changed into translucent flexible plastic or resin, semitransparent type eyeshade is formed, its
He is same as Example 1.The eyeshade is primarily adapted for use in amblyopia eye vision and has recovered normal but be still below Dominant eye, is treated to consolidate
Effect, can depending on it is near when cover Dominant eye.Using the intelligent eyeshade of this type.Patient, so-and-so, man, 4 years old, central fixation property height
The amblyopia of ametropic, it is necessary to whole day is covered, we just design monitoring whole day the covering time and covering amount, cover quality with
And covering the prompting omitted, it is ensured that occlusion therapy is whole, high-quality completion, when abandoning from overcover occurs in patient, intelligence
Change eyeshade is sent at once warns the prompting patient that blows a whistle to restart new treatment.Treatment later stage patient's vision reach twenty-twenty vision but
It is that stereoscopic vision is 100 seconds angles, stereopsis is substantially abnormal, it is necessary to the training of stereoscopic vision be carried out, while being also required to carry out not
Complete hiding consolidates eyesight, now can just change intelligent eyeshade into translucent state, can not only suppress Dominant eye but also can be with
Set up binocular stereo vision.Covering amount and covering time are recalculated, and quantification carries out occlusion therapy.
Embodiment 4
Patient, so-and-so, man, 9 years old, central fixation amblyopia are, it is necessary to cover strong eye, but patient is needed during school learns
Using eyes, the type patient needs to calculate the covering time of design monitoring recovery time and covering amount, covers quality and screening
Cover the prompting omitted, it is ensured that occlusion therapy is whole, high-quality completion, when abandoning from overcover occurs in patient, intelligent eye
Cover is sent at once warns the prompting patient that blows a whistle to restart new treatment.Treatment can produce other discomforts if whole day is covered,
Intelligent eyeshade can be just designed as to intermittent covering daily, as shown in figure 4, can not only suppress Dominant eye but also can complete to hide
Lid task, clearly carries out quantification and carries out occlusion therapy.Other are same as Example 1.
Embodiment 5:
As shown in figure 5, two eyeshades are used alternatingly, alternating treatment is carried out to two eyes of patient, eyes is formed and hands over
For covering type eyeshade, other are same as Example 1.The eyeshade of the type is primarily adapted for use in ametropic amblyopia and monocular squint
Property amblyopia, the situation of eyes amblyopia eyesight not etc., eyes equivalent alternately covers.Patient, so-and-so, man, 6 years old, central fixation was weak
Depending on hyperpresbyopia is ametropia, it is necessary to cover eyes, but patient needs to use eyes during school learns, the type is suffered from
Person needs to calculate covering time and covering amount, cover quality and covering the prompting omitted for design monitoring recovery time, it is ensured that
Occlusion therapy is whole, high-quality completion, and when abandoning from overcover occurs in patient, intelligent eyeshade sends warning at once and blown a whistle
Patient is reminded to restart new treatment.Eyes are treated simultaneously, if whole day, which is covered, can produce other discomforts, it is possible to by intelligence
Eyeshade can be changed to be designed as alternately covering daily, quantification is clearly carried out and carry out occlusion therapy, promote eyes far, closely to use,
Reach the purpose that eyesight increases.The covering time is designed as equivalent, complete monitoring, abandons and blow a whistle, record covering time total amount etc., really
Protect and cover high-quality complete.
Bibliography
1. the definition of sweet dawn tinkling of pieces of jade amblyopias, classification and the standard of curative effect evaluation [J] China strabismus and pediatric ophthalmology magazine,
1996,4(3):97.
2. Shao renders meritorious service, Guo Yongsheng, virtue amblyopias define the discrimination of " Consensus of experts " science and diagnose goldstandard [A] with amblyopia before marquis
14th international ophthalmology academic conference, the 14th international optometry academic conference, the 3rd moulding science of international cornea
Conference collection of thesis [C] .2014.
3.Xin mei Wang,Dongmei Cui,Ling Zheng,et al.Combination of blood
oxygen level-dependent functional magnetic resonance imaging and visual
evoked potential recordings for abnormal visual cortex in two types of
amblyopia[J].Molecular Vision,2012,18:909.
4. pair crystalline substance, the grand of State of Zhao payes attention to the Chinese ophthalmology medical journal (electronics of renewal [J] of amblyopia Clinics and Practices idea
Version), 2014,4 (2):1-4.
5.Lowel S,Engelmann R.Neuroanatomical and neurophysiological
consequences of strabismus:changes in the structural and functional
organization ofthe primary visual cortex in cats with alternating fixation
and strabismic amblyopia[J].Strabismus,2002,10(2):95-105.
6. permitted Na, the international ophthalmology magazines of progress [J] of Li Ping China strabismic amblyopia pathogenesis, 2006,6 (5):
1139-1142.
7. Luo Yu beautiful jades, Tao Lijuan, Yang Junfang, wait clinical observation [J] of different type children with amblyopia stereoscopic vision situations
International ophthalmology magazine, 2014,14 (3):566-568.
8.Greenwood JA,Tailor VK,Sloper JJ,et al.Visual acuity,crowding,and
stero-vision are linked in children with and without amblyopia[J].Invest
Ophthalmol Vis Sci,2012,53(12):7655-7665.
9.Weakley DR Jr,Birch E.The role of anisometropia in the development
of accommodative esotropia[J].Trans Am Ophthalmol Soc,2000,98:71-76.
10. first kingfisher English, Dai Chunhua, Song Xiufen wait anisometropic amblyopia of children retina optical coherence tomographies to grind
Study carefully [J] China strabismus and pediatric ophthalmology magazine, 2014,22 (2):31-34.
11. Zhou Yanli, Zhang Yanfang, Qian Zhigang, wait the international eye of pathogenesis and newest therapeutic advance [J] of children's myopias
Section's magazine, 2014,14 (5):846-848.
12.Von Noorden GK.Binocular vision and ocular motility.5th ed.St
Louis:The CV Mosby,1996:216-220.
13.Von Noorden GK, Campos EC.Amblyopia.In:von Noorden GK,Campos EC,
eds.Binocular vision and ocular motility:Theory and Management of Strabismus,
6th ed.St.Louis:Mosby,2002:538-558.
14. Zhou Weiwei, Liu Chunmin, Soviet Union completely think, long sight children with amblyopia retinal nerve fiber layer thickness is waited to analyze [J]
China's strabismus and pediatric ophthalmology magazine, 2010,18 (4):145.
15.Botabckova TK,Kurgambckova NS.Optical coherent tomography in the
diagnosis of amblyopia[J].Invest Ophtalmol Vis Sci,2005,121(5):28.
16.Quoc EB,Dclcpine B,Tran TH.Thickness of retinal nerve fiber layer
and macular volume in chidren and adults with strabismic and anisometropic
amblyopia[J].Journal Francais D Ophtalmologie,2009,32(7):488.
17.Salchow DJ,Olcynikov YS,Chiang MF,et al.Retinal nerve fiber layer
thickness in normal chidren measured with optical coherence tomography[J]
.Ophthalmology,2006,113(5):786.
18.Moseley MJ,Fielder AR,Stewart CE.The optical treatment of
amblyopia[J].Optom Vis Sci,2009,86(8):629-633.
19.Pradhan ZS,Mittal R,Jacob P.Rigid gas-permeable contact lenses for
visual rehabilitation of traumatized eyes in children[J].Cornea,2014,33(5):
486-489.
20. old be, Sun Qiang, Zhang Cong, wait to wear RGP treatment anisometropic amblyopias and inquire into the international ophthalmology magazines of [J],
2010,10(10):2006-2007.
21.Loudon SE,Polling JR,Simonsz B,et al.Objective survey of the
prescription of occlusion therapy for amblyopia[J].Graefes Arch Clin Exp
Ophthalmol,2004,242:736-740.
22.Hug T.Full-time occlusion compared to part-time occlusion for the
treatment of amblyopia[J].Optometry,2004,75:241-244.
23.Repka MX,Beck RW,Holmes JM,et al.A randomized trial of patching
regimens for treatment of moderate amblyopia in children[J].Arch Ophthalmol,
2003,121:603-611.
24.Holmes JM,Kraker RT,Beck RW,et al.A randomized trial of prescribed
patching regimens for treatment of severe amblyopia in chidren[J]
.Ophthalmology,2003,110:2075-2087.
25.Matta NS,Silbert DI.Part-time vs.full-time occlusion for
amblyopia:evidence for part-time patching[J].Am Orthopt J.2013,63:14-8.
26.Simon JW,Parks MM,Price EC.Severe visual loss resulting from
occlusion therapy for amblyopia[J].JPediatr Ophthalmol Strabismus,1987,24:
244-246.
27.AR Medghalchi,S Dalili.ARandomized Trial of Atropine vs Patching
for Treatment of Moderate Amblyopia[J].Iran Red Crescent Med J,2011,13(8):
578.
28.The Pediatric Eye Diseases Investigator Group.A randomized trial
of atropine vs patching for treatment of moderate amblyopia[J].Arch
Ophthalmol,2008,126(8):1039-1044.
29.Repka MX,Kraker RT,Bech RW,et al.Treatment of severe amblyopia
with weekend atropine:Results from 2 randomized clinical trial[J].JAAPOS,
2009,13(3):258-263.
30. swallow is built up the Army, Peng Huican, Wu's orange perfume, atropines penalization is waited to treat the clinical sight of children whose monocular amblyopia with covering method
Examine the international ophthalmology magazines [J] of, 2008,8 (4):777-778.
31.France TD,France LW.Optical penalization versus part-time
occlusion treatment[J].JAAPOS,1999,3,341-343.
32.Saltarelli DP,Motley WW.Optical penalization with contact lenses
for children with unilateral aphakia:an alternative to patching[J].Eye
Contact Lens,2013,39(6):405-409.
33.Simon JW,Sood AB,Mali JO.Combined optical and atropine treatment
of children with residual amblyopia after atropine penalization[J].J Pediatr
Ophthalmol Strabismus,2013,26:50.
34.Li R.Effect of L-dopamethylester on visual cortex injury induced
by amblyopia and its underlying mechanism[J].Neurosci Lett,2012,508(2):95.
35 Ni Zhao, therapeutic advance [J] Medical reviews of Zhang Li's amblyopias, 2015,21 (13):2402-2404.
36. Wang Huan swallows, above the average age for marriage 50 observation of curative effect [J] the osiery medical science of amblyopia of the flat CDPCs treatment of Xu's generation, 2009,
22(2):77-78.
37. what clear swallow, Wang Lihua, observation of curative effect [J] China of the oral CDPC treatment amblyopias of such as sweet dawn tinkling of pieces of jade is tiltedly
Depending on pediatric ophthalmology magazine, 2012,20 (2):63-64.
38. prosperous crystal-clear, Jiang Chunguang older children amblyopias therapeutic advance [J] worlds ophthalmology magazine, 2010,10 (90):
1734-1735.
39.Mohammad A Rashad.Pharmacological enhancement of treatment for
amblyopia[J].Clinical Ophthalmology,2012,6:409.
40.Fresina M,Dickmann A,Salerni A,et al.Effect of oral CDP-choline on
visual function in young amblyopic patients[J].Graefes Arch Clin Exp
Ophthalmol,2008,246(1):143-150.
41. Li Jie, Hao Huiling, efficacy analysis [J] that children's paracentral fixation amblyopia is treated in after images ruling by law in Liu Gansu Province Guizhou Province are international
Ophthalmology magazine, 2009,9 (5):996-997.
42. Xu Xing is intelligent, the international ophthalmology magazines of 255 observation of curative effect [J] of Zhang Wufeng complex treatments children's myopia, and 2015,
15(11):2021-2022.
43. effect analysis [J] China strabismus and the pediatric ophthalmology magazine of Yuan Jing General treatment of children with amblyopia,
2011,19(4):173.
44. the TCM investigation progress [J] of the prosperous amblyopia treatments of Wei Yun, Chinese Medicine guide, 2014,16 (6):982-983.
45. poplar builds virtue, woods swallow, Huang Xuqing waits herbal ion penetrations to treat adolescent myopia, amblyopia and visual fatigue
Clinical observation on the therapeutic effect [J] Chinese Medicine guides, 2013,20:677-678.
46. Zhao kindly helps secure the success of, Zhao Yong, Zhang Haimei, is waited to be good for bright soup treatment 36 [J] Hebei traditional Chinese medical science of amblyopia, 2006,28 (3):
228.
47. Wang Yan, all sword electric plum-blossom acupuncture needles kowtow clinical observation [J] the Beijing University of Chinese Medicine of thorn therapy for treating children's myopia
Journal, 2012,35 (2):136-140.
48. Zhang Mao plum, Meng Yonghui, Liu Yang are pinched in observation of curative effect [J] of ridge and Acupressure auxiliary treatment children's myopia
State community doctor (medical speciality), 2012,14 (18):249-250.
49.Handa T,Ishikawa H,Shoji N,et al.Modified iPad for treatment of
amblyopia:a preliminary study[J].JAAPOS,2015,19(6):552-554.
Above-mentioned technical proposal only embodies the optimal technical scheme of technical solution of the present invention, those skilled in the art
Some of which part may be made some variation embodies the present invention principle, belong to protection scope of the present invention it
It is interior.
Claims (10)
1. a kind of intelligent eye-cover for weak sight of monitoring in real time, including eyeshade body (1), it is characterised in that on eyeshade body
Monitor (2), power supply (3), buzzer (4), red prompt light (5) and the green warning light (6) of monitoring pupil position are provided with,
Eyeshade body interior is built-in with the monitoring chip (7) for analyzing pupil position data, and the signal input port of monitoring chip leads to
The output port for crossing the data wire built in eyeshade body and monitor is connected, and the power end of monitoring chip passes through built in eyeshade body
Wire and the positive and negative electrode of power supply connect, a current output terminal of the monitoring chip passes through leading built in eyeshade body
The power interface connection of line and buzzer, No. two current output terminals of the monitoring chip pass through the wire built in eyeshade body
It is connected with the power interface of red prompt light, No. three current output terminals of the monitoring chip pass through leading built in eyeshade body
Line is connected with the power interface of green warning light.
2. the intelligent eye-cover for weak sight of real-time monitoring according to claim 1, it is characterised in that the monitor (2)
It is the minisize pick-up head with detection pupil position function.
3. the intelligent eye-cover for weak sight of real-time monitoring according to claim 2, it is characterised in that the monitor (2)
It is model TE810H microcam.
4. the intelligent eye-cover for weak sight of real-time monitoring according to claim 1, it is characterised in that the monitoring chip
(7) be the production of magnificent health electronics model HG768 monitoring chip.
5. the intelligent eye-cover for weak sight of real-time monitoring according to claim 4, it is characterised in that the monitoring chip
(7) wireless data transmission is carried out by LAN and computer by the wireless module built in it.
6. the intelligent eye-cover for weak sight of real-time monitoring according to claim 1, it is characterised in that the red prompt light
And green warning light (6) is all the LED luminescent crystals wrapped up using silica gel (5).
7. the intelligent eye-cover for weak sight of real-time monitoring according to claim 1, it is characterised in that the eyeshade body
(1) eyes are covered by way of frenulum.
8. the intelligent eye-cover for weak sight of real-time monitoring according to claim 7, it is characterised in that the eyeshade body
(1) it is the rectangular sheet structure that is made of elastic cotton or cloth, and the edge of eyeshade body is handled by chamfering structure.
9. the real-time intelligent eye-cover for weak sight of monitoring according to claim 1, it is characterised in that the power supply (3) is
Lithium battery, the lithium battery is detachably arranged on eyeshade body.
10. the intelligent eye-cover for weak sight of real-time monitoring according to claim 2, it is characterised in that the monitor (2)
Gather iris positional information or infrared reflection information or eye moves number information, and transmit this information to monitoring chip analysis pupil
The position in hole.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710021752.XA CN106963547A (en) | 2017-01-12 | 2017-01-12 | The intelligent eye-cover for weak sight of monitoring in real time |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710021752.XA CN106963547A (en) | 2017-01-12 | 2017-01-12 | The intelligent eye-cover for weak sight of monitoring in real time |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106963547A true CN106963547A (en) | 2017-07-21 |
Family
ID=59334741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710021752.XA Pending CN106963547A (en) | 2017-01-12 | 2017-01-12 | The intelligent eye-cover for weak sight of monitoring in real time |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106963547A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108378986A (en) * | 2018-03-06 | 2018-08-10 | 谢红波 | Intelligent amblyopia of real-time supervision covers eye-shade |
CN111513922A (en) * | 2020-04-10 | 2020-08-11 | 温州医科大学附属眼视光医院 | Light-sensitive amblyopia treatment covering eyeshade capable of timing |
CN113329787A (en) * | 2019-06-27 | 2021-08-31 | 丹尼斯·F·格罗斯 | Adjustable treatment mask |
CN114469515A (en) * | 2022-03-31 | 2022-05-13 | 欧普康视科技股份有限公司 | Intelligent amblyopia covering eyeshade |
CN115864915A (en) * | 2023-02-23 | 2023-03-28 | 美视康健(吉林)医疗设备有限公司 | Driving device of Haiding lattice brush |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552854A (en) * | 1992-09-14 | 1996-09-03 | Nikon Corporation | Visual line detection device and camera equipped therewith |
US5879292A (en) * | 1997-10-09 | 1999-03-09 | Edward A. Sternberg | Bandage including data acquisition components |
US20030189687A1 (en) * | 2002-04-05 | 2003-10-09 | Renard Paula A. | Bifocal spectacles for computer users and display device therefor |
CN2616171Y (en) * | 2003-01-10 | 2004-05-19 | 北京宝润通科技开发有限责任公司 | Multi-purpose infrared video-frequency eyeshade |
US20050179865A1 (en) * | 2004-02-18 | 2005-08-18 | Hsieh Chi W. | Eye activity monitoring apparatus and system |
US20150035744A1 (en) * | 2013-07-30 | 2015-02-05 | Steve Robbins | Near-eye optic positioning in display devices |
CN105250120A (en) * | 2015-11-27 | 2016-01-20 | 刘东光 | Intelligent dynamic compound vision improving instrument |
CN106030382A (en) * | 2014-02-18 | 2016-10-12 | 埃西勒国际通用光学公司 | Method for optimizing an optical lens equipment for a wearer |
CN106037626A (en) * | 2016-07-12 | 2016-10-26 | 吴越 | Head-mounted visual field inspector |
-
2017
- 2017-01-12 CN CN201710021752.XA patent/CN106963547A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552854A (en) * | 1992-09-14 | 1996-09-03 | Nikon Corporation | Visual line detection device and camera equipped therewith |
US5879292A (en) * | 1997-10-09 | 1999-03-09 | Edward A. Sternberg | Bandage including data acquisition components |
US20030189687A1 (en) * | 2002-04-05 | 2003-10-09 | Renard Paula A. | Bifocal spectacles for computer users and display device therefor |
CN2616171Y (en) * | 2003-01-10 | 2004-05-19 | 北京宝润通科技开发有限责任公司 | Multi-purpose infrared video-frequency eyeshade |
US20050179865A1 (en) * | 2004-02-18 | 2005-08-18 | Hsieh Chi W. | Eye activity monitoring apparatus and system |
US20150035744A1 (en) * | 2013-07-30 | 2015-02-05 | Steve Robbins | Near-eye optic positioning in display devices |
CN106030382A (en) * | 2014-02-18 | 2016-10-12 | 埃西勒国际通用光学公司 | Method for optimizing an optical lens equipment for a wearer |
CN105250120A (en) * | 2015-11-27 | 2016-01-20 | 刘东光 | Intelligent dynamic compound vision improving instrument |
CN106037626A (en) * | 2016-07-12 | 2016-10-26 | 吴越 | Head-mounted visual field inspector |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108378986A (en) * | 2018-03-06 | 2018-08-10 | 谢红波 | Intelligent amblyopia of real-time supervision covers eye-shade |
CN113329787A (en) * | 2019-06-27 | 2021-08-31 | 丹尼斯·F·格罗斯 | Adjustable treatment mask |
CN111513922A (en) * | 2020-04-10 | 2020-08-11 | 温州医科大学附属眼视光医院 | Light-sensitive amblyopia treatment covering eyeshade capable of timing |
CN111513922B (en) * | 2020-04-10 | 2022-05-17 | 温州医科大学附属眼视光医院 | Light-sensitive amblyopia treatment covering eyeshade capable of timing |
CN114469515A (en) * | 2022-03-31 | 2022-05-13 | 欧普康视科技股份有限公司 | Intelligent amblyopia covering eyeshade |
CN115864915A (en) * | 2023-02-23 | 2023-03-28 | 美视康健(吉林)医疗设备有限公司 | Driving device of Haiding lattice brush |
CN115864915B (en) * | 2023-02-23 | 2023-06-06 | 美视康健(吉林)医疗设备有限公司 | Driving device of Haiding brush |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106963547A (en) | The intelligent eye-cover for weak sight of monitoring in real time | |
CN104382729A (en) | Vision correction training system and method | |
Peppard | Sight without glasses | |
CN208065336U (en) | The intelligent eye-cover for weak sight of monitoring in real time | |
RU2606180C1 (en) | Method of treating and preventing myopia and accommodation spasm by badminton | |
Silva et al. | Analysis of the disturbances caused by intraocular forced convection mechanism failure | |
CN101224151A (en) | Amblyopia vision increasing treatment method and system thereof | |
CN106214439A (en) | A kind of Chinese physical therapy alleviates children's myopia using system and using method thereof | |
CN205539783U (en) | Adopt spallation crack of going of crack lens preparation to make up mirror | |
Dhote | Eye exercises-an eyesight rejuvenation therapy | |
CN106943230A (en) | A kind of visual rehabilitation eyeshade | |
CN201073376Y (en) | Novel myopic eye massage and treatment equipment | |
CN103860731A (en) | Pure traditional Chinese medicine preparation for treating eye disease | |
CN103860363A (en) | Vision correction glasses and use method thereof | |
RU2150253C1 (en) | Method for treating anisometropic refraction amblyopia | |
Deng et al. | Postoperative Visual Rehabilitation in Children with Lens Diseases | |
CN216222268U (en) | Myopia therapeutic instrument | |
Weiner et al. | Monitoring ocular changes that may accompany use of dental appliances and/or osteopathic craniosacral manipulations in the treatment of TMJ and related problems | |
Liping et al. | Formation mechanism and clinical application of the dominant eye | |
Przekoracka-Krawczyk et al. | Visual Therapy in Open Space Rehabilitation of Acquired Visual Field Defect | |
Hansell | The ocular muscles | |
Weeks | Ocular headache | |
Kumar | ROLE OF TARPANA WITH PHALTRIKADI GHRITA IN THE MANAGEMENT OF DWITIYA PATALGATA TIMIRA WSR TO PRESBYOPIA | |
Zhao et al. | Rehabilitation Therapy of Neurological Training of Visual Impairment | |
CN113693818A (en) | Bionic myopia and amblyopia comprehensive therapeutic instrument with laser for increasing peripheral visual field stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170721 |
|
WD01 | Invention patent application deemed withdrawn after publication |